SGLT2i treatment at the beginning of real time exposure in a HFrEF population

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Associate Professor Vlad Damian Vintila

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

4 More presentations in this session

Presentation thumbnail

What factors are associated with myocardial recovery following admission for acute heart failure? Study in patients with de novo diagnosis and reduced left ventricular ejection fraction

Mr V. Donoso (Valencia, ES)

Abstract Slides Video

Presentation thumbnail

Nation-wide use of guideline-directed medical therapies in heart failure across the ejection fraction range: The HECMOS study

Doctor I. Leontsinis (Athens, GR)

Abstract Slides Video

Presentation thumbnail

The daily challenges to patients posed by diuretic therapy; what they are and what do patients do?

Doctor G. Bruno (Limerick, IE)

Abstract Slides Video

Presentation thumbnail

CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and cardiorenal syndrome

Mr G. Nunez Marin (Valencia, ES)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy 6

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

Congress Presentation

A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

Congress Presentation

Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources